<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00619918</url>
  </required_header>
  <id_info>
    <org_study_id>CCI-06-00271</org_study_id>
    <nct_id>NCT00619918</nct_id>
  </id_info>
  <brief_title>Nebulized Hypertonic Saline for Bronchiolitis</brief_title>
  <official_title>Nebulized Hypertonic Saline for Treatment of Viral Bronchiolitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital &amp; Research Center Oakland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thrasher Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to examine the effect of nebulized 3% hypertonic saline in the treatment of
      viral bronchiolitis. The investigators hypothesize that nebulized 3% saline will decrease
      rate of hospital admission, decrease clinical severity scores, and decrease length of stay.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bronchiolitis is the most common viral respiratory infection in young children and infants.
      It is responsible for hundreds of thousands of outpatient visits and hospitalizations every
      year. Hypertonic saline may decrease swelling in the lung tissue, improve the patient's
      ability to clear secretions, and decrease nasal congestion. Hypertonic saline nebulizations
      have already been used effectively in patients with cystic fibrosis and in a few small trials
      on infants with bronchiolitis. Patients who come to the emergency department or inpatient
      ward of two urban free-standing pediatric hospitals in California between December and April
      and are diagnosed with bronchiolitis will be randomized into two groups- the control group
      will receive nebulized 0.9% normal saline, while the study group will receive nebulized 3%
      hypertonic saline. Nebulizations will be pretreated with albuterol, to prevent the
      theoretical risk of increased wheezing in patients with undiagnosed underlying asthma.
      Patients will be given up to 3 nebulizations in the emergency department, after which time
      the attending physician will decide whether admission to the hospital is required. Patients
      who are admitted will continue to receive the same nebulized treatment every 8 hours until
      discharged. Additional interventions such as epinephrine treatments and antibiotics can be
      ordered as indicated by the patient care team.

      Investigators will measure symptom severity before and after treatments using the respiratory
      distress assessment instrument (RDAI). The investigators will compare rates of being admitted
      to the hospital in each group. The investigators will also compare RDAI scores, average
      length of stay, number of additional respiratory treatments needed, number of hours requiring
      oxygen, amount of IV fluid needed, and frequency of adverse effects. The investigators
      hypothesize that nebulized hypertonic saline will be a safe, cost-effective, and efficacious
      therapy which can be utilized in the outpatient setting to prevent hospital admission, as
      well as decrease length of stay for patients who require admission. Given the significant
      disease burden of viral bronchiolitis, the potential impact is substantial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Admission Rate</measure>
    <time_frame>1 day</time_frame>
    <description>Patients enrolled in the ED who required inpatient admission. Patients who required admission but were transferred to another facility due to lack of available beds were considered admitted for this outcome. Note, neither study site has an observation unit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Length of Stay</measure>
    <time_frame>1 month</time_frame>
    <description>Length of stay defined as date of discharge minute date of admission.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in RDAI Score</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hours of Oxygen Use</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IV Fluid Use</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supplemental Medication Use</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">447</enrollment>
  <condition>Bronchiolitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3% saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebulized 3% saline</intervention_name>
    <description>4 ml inhaled q8h</description>
    <arm_group_label>1</arm_group_label>
    <other_name>3% saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>normal saline</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosis of viral bronchiolitis

          -  between November and April

        Exclusion Criteria:

          -  prematurity &lt; 34 weeks

          -  chronic lung disease

          -  congenital heart disease

          -  history of wheezing, asthma or albuterol use

          -  tracheostomy status

          -  need for intensive care of assisted ventilation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Wu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Childrens Hospital Los Angeles/University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Childrens Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital &amp; Research Center at Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2008</study_first_submitted>
  <study_first_submitted_qc>February 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2008</study_first_posted>
  <results_first_submitted>July 29, 2013</results_first_submitted>
  <results_first_submitted_qc>July 29, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 10, 2013</results_first_posted>
  <last_update_submitted>July 29, 2013</last_update_submitted>
  <last_update_submitted_qc>July 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital Los Angeles</investigator_affiliation>
    <investigator_full_name>Susan Wu</investigator_full_name>
    <investigator_title>Assistant Professor of Clinical Pediatrics</investigator_title>
  </responsible_party>
  <keyword>bronchiolitis</keyword>
  <keyword>hypertonic saline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiolitis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited beginning March 2008 and April 2011, only during months of bronchiolitis season (November through April). Recruitment occurred in the emergency department and general medical inpatient units at 2 urban tertiary free-standing children's hospitals in the U.S.</recruitment_details>
      <pre_assignment_details>No patients were excluded after enrollment but before randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Hypertonic Saline</title>
          <description>3% NaCl, 4 ml, via updraft wall nebulizer:
In ED: every 20 minutes up to 3 doses
In Inpatient: every 8 hours until discharge</description>
        </group>
        <group group_id="P2">
          <title>Normal Saline</title>
          <description>0.9% NaCl, 4 ml, via updraft wall nebulizer:
In ED: every 20 minutes up to 3 doses
In Inpatient: every 8 hours until discharge</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="230"/>
                <participants group_id="P2" count="217"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="210"/>
                <participants group_id="P2" count="195"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Transfer to outside facility</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Left before receiving first dose</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hypertonic Saline</title>
          <description>3% NaCl, 4 ml, via updraft wall nebulizer:
In ED: every 20 minutes up to 3 doses
In Inpatient: every 8 hours until discharge</description>
        </group>
        <group group_id="B2">
          <title>Normal Saline</title>
          <description>0.9% NaCl, 4 ml, via updraft wall nebulizer:
In ED: every 20 minutes up to 3 doses
In Inpatient: every 8 hours until discharge</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="230"/>
            <count group_id="B2" value="217"/>
            <count group_id="B3" value="447"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="230"/>
                    <measurement group_id="B2" value="217"/>
                    <measurement group_id="B3" value="447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.55" spread="0.42"/>
                    <measurement group_id="B2" value="0.53" spread="0.43"/>
                    <measurement group_id="B3" value="0.54" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="230"/>
                    <measurement group_id="B2" value="217"/>
                    <measurement group_id="B3" value="447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Admission Rate</title>
        <description>Patients enrolled in the ED who required inpatient admission. Patients who required admission but were transferred to another facility due to lack of available beds were considered admitted for this outcome. Note, neither study site has an observation unit.</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hypertonic Saline</title>
            <description>3% NaCl, 4 ml, via updraft wall nebulizer:
In ED: every 20 minutes up to 3 doses
In Inpatient: every 8 hours until discharge</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>0.9% NaCl, 4 ml, via updraft wall nebulizer:
In ED: every 20 minutes up to 3 doses
In Inpatient: every 8 hours until discharge</description>
          </group>
        </group_list>
        <measure>
          <title>Admission Rate</title>
          <description>Patients enrolled in the ED who required inpatient admission. Patients who required admission but were transferred to another facility due to lack of available beds were considered admitted for this outcome. Note, neither study site has an observation unit.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Admitted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141"/>
                    <measurement group_id="O2" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Length of Stay</title>
        <description>Length of stay defined as date of discharge minute date of admission.</description>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hypertonic Saline</title>
            <description>3% NaCl, 4 ml, via updraft wall nebulizer:
In ED: every 20 minutes up to 3 doses
In Inpatient: every 8 hours until discharge</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>0.9% NaCl, 4 ml, via updraft wall nebulizer:
In ED: every 20 minutes up to 3 doses
In Inpatient: every 8 hours until discharge</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Stay</title>
          <description>Length of stay defined as date of discharge minute date of admission.</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.87" spread="2.00"/>
                    <measurement group_id="O2" value="2.86" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in RDAI Score</title>
        <time_frame>1 day</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hours of Oxygen Use</title>
        <time_frame>14 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IV Fluid Use</title>
        <time_frame>14 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Supplemental Medication Use</title>
        <time_frame>14 days</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Hypertonic Saline</title>
          <description>3% NaCl, 4 ml, via updraft wall nebulizer:
In ED: every 20 minutes up to 3 doses
In Inpatient: every 8 hours until discharge</description>
        </group>
        <group group_id="E2">
          <title>Normal Saline</title>
          <description>0.9% NaCl, 4 ml, via updraft wall nebulizer:
In ED: every 20 minutes up to 3 doses
In Inpatient: every 8 hours until discharge</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ICU admission</sub_title>
                <description>Patients requiring admission or transfer to the PICU or NICU</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="225"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Worsening cough</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Parent or provider perception of worsening cough</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Albuterol administered before each study treatment
Did not reach subject accrual goals
Number of patients recruited from inpatient unit too small to analyze separately</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Susan Wu</name_or_title>
      <organization>Children's Hospital Los Angeles</organization>
      <phone>323-361-6177</phone>
      <email>suwu@chla.usc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

